SCHEMBL384804

SCHEMBL384804

Cc1cc(-c2cc(-c3cccc(OCC(=O)NCc4ccccc4)c3)[nH]c(=O)n2)ccc1O

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDC7 O00311 3/20 0.60
PIM1 P11309 2/20 0.60
CSNK2A2 P19784 1/20 0.60
CLK1 P49759 1/20 0.60
GSK3B P49841 1/20 0.60
CSNK2B P67870 1/20 0.60
CSNK2A1 P68400 1/20 0.60
CSNK2A3 Q8NEV1 1/20 0.60
ADORA2B P29275 4/20 0.46
ADORA2A P29274 3/20 0.46
KMT2A Q03164 2/20 0.45
HPGD P15428 1/20 0.45
ERCC1 P07992 1/20 0.45
ERCC4 Q92889 1/20 0.45
SMN1; SMN2 Q16637 4/20 0.43
ABL1 P00519 1/20 0.43
GLA P06280 1/20 0.42
KDM4E B2RXH2 1/20 0.42
DHODH Q02127 1/20 0.42
ADORA3 P0DMS8 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3329807 0.93 CDC7 (0.53) CDC7PIM1CSNK2A2CLK1GSK3B
SCHEMBL3328591 0.93 PIM1 (0.52) CDC7PIM1CSNK2A2CLK1GSK3B
SCHEMBL3334149 0.93 PIM1 (0.52) CDC7PIM1CSNK2A2CLK1GSK3B
SCHEMBL3328825 0.93 PIM1 (0.52) CDC7PIM1CSNK2A2CLK1GSK3B
SCHEMBL3331257 0.92 CDC7 (0.52) CDC7PIM1CSNK2A2CLK1GSK3B
SCHEMBL3335318 0.91 CDC7 (0.51) CDC7PIM1CSNK2A2CLK1GSK3B
SCHEMBL3325453 0.89 CDC7 (0.59) CDC7PIM1CSNK2A2CLK1GSK3B
SCHEMBL3329638 0.89 CDC7 (0.50) CDC7PIM1CSNK2A2CLK1GSK3B
SCHEMBL3330085 0.89 PIM1 (0.54) CDC7PIM1CSNK2A2CLK1GSK3B
SCHEMBL3335075 0.88 CDC7 (0.57) CDC7PIM1CSNK2A2CLK1GSK3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8101625-B2 Pyrimidinones as Casein Kinase II (CK2) modulators EXELIXIS, INC. (US) 2012-01-24 US claimed
EP-1948617-B1 PYRIMIDINONES AS CASEIN KINASE II (CK2) MODULATORS EXELIXIS INC (US) 2011-07-27 EP claimed
US-20090215803-A1 Pyrimidinones as Casein Kinase II (CK2) Modulators EXELIXIS, INC. 2009-08-27 US claimed
US-8101625-B2 Pyrimidinones as Casein Kinase II (CK2) modulators EXELIXIS, INC. (US) 2012-01-24 US disclosed
US-8101625-B2 Pyrimidinones as Casein Kinase II (CK2) modulators EXELIXIS, INC. (US) 2012-01-24 US disclosed
US-8101625-B2 Pyrimidinones as Casein Kinase II (CK2) modulators EXELIXIS, INC. (US) 2012-01-24 US disclosed
EP-1948617-B1 PYRIMIDINONES AS CASEIN KINASE II (CK2) MODULATORS EXELIXIS INC (US) 2011-07-27 EP disclosed
EP-1948617-B1 PYRIMIDINONES AS CASEIN KINASE II (CK2) MODULATORS EXELIXIS INC (US) 2011-07-27 EP disclosed
US-20090215803-A1 Pyrimidinones as Casein Kinase II (CK2) Modulators EXELIXIS, INC. 2009-08-27 US disclosed
US-20090215803-A1 Pyrimidinones as Casein Kinase II (CK2) Modulators EXELIXIS, INC. 2009-08-27 US disclosed
US-20090215803-A1 Pyrimidinones as Casein Kinase II (CK2) Modulators EXELIXIS, INC. 2009-08-27 US disclosed
EP-1948617-A2 PYRIMIDINONES AS CASEIN KINASE II (CK2) MODULATORS Exelixis, Inc. (US) 2008-07-30 EP disclosed
WO-2007048065-A2 PYRIMIDINONES AS CASEIN KINASE II (CK2) MODULATORS EXELIXIS, INC. (US) 2007-04-26 WO disclosed
WO-2007048065-A2 PYRIMIDINONES AS CASEIN KINASE II (CK2) MODULATORS EXELIXIS, INC. (US) 2007-04-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090215803-A1 Pyrimidinones as Casein Kinase II (CK2) Modulators CSNK2A1, CSNK1A1, CSNK2A2 CDC7 536/4885PIM1 429/4885CSNK2A2 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.